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Abstract
It has been suggested that genetic susceptibility plays an important role in the pathogenesis of diabetic nephropathy. A
large-scale genotyping analysis of gene-based single nucleotide polymorphisms (SNPs) in Japanese patients with type 2
diabetes identified the gene encoding acetyl-coenzyme A carboxylase beta (ACACB) as a candidate for a susceptibility to
diabetic nephropathy; the landmark SNP was found in the intron 18 of ACACB (rs2268388: intron 18 +4139 C . T,
p=1.4610
26, odds ratio=1.61, 95% confidence interval [CI]: 1.33–1.96). The association of this SNP with diabetic
nephropathy was examined in 9 independent studies (4 from Japan including the original study, one Singaporean, one
Korean, and two European) with type 2 diabetes. One case-control study involving European patients with type 1 diabetes
was included. The frequency of the T allele for SNP rs2268388 was consistently higher among patients with type 2 diabetes
and proteinuria. A meta-analysis revealed that rs2268388 was significantly associated with proteinuria in Japanese patients
with type 2 diabetes (p=5.35610
28, odds ratio=1.61, 95% Cl: 1.35–1.91). Rs2268388 was also associated with type 2
diabetes–associated end-stage renal disease (ESRD) in European Americans (p=6610
24, odds ratio=1.61, 95% Cl: 1.22–
2.13). Significant association was not detected between this SNP and nephropathy in those with type 1 diabetes. A
subsequent in vitro functional analysis revealed that a 29-bp DNA fragment, including rs2268388, had significant enhancer
activity in cultured human renal proximal tubular epithelial cells. Fragments corresponding to the disease susceptibility
allele (T) had higher enhancer activity than those of the major allele. These results suggest that ACACB is a strong candidate
for conferring susceptibility for proteinuria in patients with type 2 diabetes.
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Diabetic nephropathy is a leading cause of end-stage renal
disease (ESRD) in Western countries [1] and in Japan [2]. The
rising incidence of diabetic nephropathy, especially among
patients with type 2 diabetes, is a serious worldwide concern in
terms of both poor prognosis and medical costs. The pathogenesis
of diabetic nephropathy has not been fully elucidated. However,
susceptibility to diabetic nephropathy appears to be determined by
multiple genetic and environmental risk factors, and genetic
susceptibility plays an important role in its development and
progression [3,4].
Both candidate gene approaches and genome-wide linkage
analyses have suggested several candidate genes with potential
impact on diabetic nephropathy. However, these findings have not
been robustly replicated [5,6], and many susceptibility genes for
diabetic nephropathy remain to be identified. The recent develop-
ment of single nucleotide polymorphism (SNP) typing technology
and insights into patterns of linkage disequilibrium (LD) in the
human genome have facilitated genome-wide association studies
(GWASs) for investigating genes associatedwithdisease susceptibility
across the entire human genome. GWASs conducted by several
independent research groups in Europe, United States [7,8] and
Japan [9,10] have identified multiple loci associated with suscepti-
bility to common complex traits, including type 2 diabetes. Recently
conducted GWAS in a population of European descent identified 4
distinct loci associated with diabetic nephropathy in type 1 diabetes.
Two of these loci were replicated in a population of the Diabetes
Control and Complications Trial (DCCT)/Epidemiology of Diabe-
tes Interventions and Complications (EDIC) cohorts [11].
With the aim of identifying loci involved in susceptibility to
common diseases, we initiated a large-scale association study using
SNPsfrom a Japanese SNP database(JSNP:http://snp.ims.u-tokyo.
ac.jp/) [12,13], that was established before creation of the HapMap
database. Through this project, we have previously identified
genes encoding solute carrier family 12 (sodium/chloride) member
3( SLC12A3: MIM 600968, Online Mendelian Inheritance in
Man: http://www.ncbi.nlm.nih.gov/omim)[14], engulfment and
cell motility 1 (ELMO1: MIM 606420)[15], and neurocalcin d
(NCALD: MIM 606722)[16] as being associated with susceptibility to
diabetic nephropathy. The ELMO1 association has been replicated
in African Americans [17] and European Americans [18].
In the present study, we extended a previous large-scale
association study for diabetic nephropathy, and provide evidence
that a SNP within the acetyl-coenzyme A (CoA) carboxylase beta
gene (ACACB; MIM: 601557) contributes to an increased
prevalence of proteinuria in patients with type 2 diabetes across
different ethnic populations.
Results
We extended our prior analysis to SNPs with p values between
0.01 and 0.05, and examined the association of these SNPs with
diabetic nephropathy in a larger study sample. In this analysis, a
SNP within ACACB showed the strongest association with diabetic
nephropathy in Japanese patients with type 2 diabetes (rs2268388:
intron 18 +4139 C . T, p=1.4610
26, odds ratio [OR] =1.61,
95% confidence interval [Cl]: 1.33–1.96, Table 1).
Subsequent LD mapping around this region with data for
264 SNPs with allele frequencies $0.1 from HapMap database
(HapMap: http://hapmap.ncbi.nlm.nih.gov/) for the Japanese,
identified a 20-kb LD block that included an original marker
SNP (rs2268388), which corresponded to a part of the ACACB
gene (Figure 1A and 1B). Therefore, we concluded that ACACB
was likely a candidate for conferring susceptibility to diabetic
nephropathy. We next analyzed 51 SNPs, including 31 tagging
SNPs, within ACACB in our Japanese population (Japanese1).
Author Summary
Although cumulative epidemiological findings have sug-
gested that genetic susceptibility plays an important role
in the pathogenesis of diabetic nephropathy, no gene
conferring susceptibility to diabetic nephropathy has been
definitively identified. In a large-scale association study of
1,312 Japanese subjects with type 2 diabetes using SNPs
from a Japanese SNP database, we show that the T-allele
of ACACB rs2268388 is associated with diabetic nephrop-
athy. We also show that the association is consistently
observed in patients with type 2 diabetes and proteinuria
across different ethnic groups, including populations of
European descent. Because a DNA fragment correspond-
ing to the disease susceptibility allele is shown to have
higher enhancer activity, we hypothesize that the increase
in the expression and/or activity of the encoded acetyl-
coenzyme A carboxylase beta contributes to the develop-
ment and progression of diabetic nephropathy. Our
present analysis provides novel insight into the pathogen-
esis of diabetic nephropathy. This finding is important
because diabetic nephropathy is a leading cause of end-
stage renal disease and affects life expectancy in subjects
with type 2 diabetes.
Table 1. Top 4 SNPs associated with diabetic nephropathy in a genome-wide screening.
Nephropathy
(a) p for HWE
(b) Control
(a) p for HWE
(b) Smallest p (model)
rs2268388 (C . T) 0.25 (413/276/48) 0.83 0.17 (379/155/18) 0.66 1.4610
26 (allelic)
Ch 12, ACACB
rs2250736 (C . T) 0.278 (394/288/63) 0.32 0.338 (233/262/55) 0.13 0.0002 (dominant)
Ch 3, CACNA1D
rs3777587 (G . A) 0.523 (156/399/191) 0.05 0.459 (166/269/120) 0.57 0.0002 (dominant)
Ch 6, CLIC5
rs7148607 (T . C) 0.34 (318/353/76) 0.06 0.39 (219/243/94) 0.13 0.0003 (recessive)
Ch 14
(a)minor allele frequencies are shown, and genotype counts are in parenthesis.
(b)p values for Hardy Weinberg equilibrium test.
doi:10.1371/journal.pgen.1000842.t001
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nominally associated with diabetic nephropathy (Figure 1C, Table
S1). No single SNP or haplotype showed stronger association with
diabetic nephropathy than the original marker SNP (Figure S1).
To validate the association of this SNP with diabetic nephrop-
athy, we examined the effects of the SNP on susceptibility to the
disease in several independent populations from different ethnic
groups (Table 2). The results indicated that the frequency of the T
allele ofrs2268388wasconsistently higheramongpatients withtype
2 diabetes with proteinuria (combined meta-analysis gave a p value
of 5.35610
28 in the Japanese, 2.34610
27 for all populations).
Significant association with ESRD was detected in the relatively
large European 2 samples (481 cases and 427 controls). The SNP
was also modestly associated with ESRD in East Asian type 2
diabetes, but the direction of association differed. Overall, the
distributionofthegenotype forrs2268388 didnot differsignificantly
between patients with ESRD and control patients having type 2
diabetes (p=0.47). No significant association was detected in
patients with type 1 diabetes having proteinuria.
We next examined the expression profile of ACACB in various
human tissues. Expression of ACACB was observed in adipose
tissue, heart and skeletal muscle, and, to a lesser extent, in the
kidney (Figure 2A). The results of in situ hybridization with normal
mouse kidney revealed that Acacb was localized to glomerular
epithelial cells and tubular epithelial cells (Figure 2B). We also
observed the expression of ACACB in cultured human renal
proximal tubular epithelial cells (hRPTECs).
To investigate the functional role of this SNP region, we
examined the effects of a 29-bp DNA fragment containing the
associated SNP (rs2268388) on transcriptional activity in cultured
hRPTECs. As shown in the Figure 3, the 29-bp DNA fragments
had significant enhancer activity (promoter alone [P]: 39.4613.1;
Figure 1. Schematic view of the association of SNPs in the ACACB region with diabetic nephropathy. (A) Pairwise correlation structure at
a 200-kb interval around SNP rs2268338 analyzed by Haploview (Haploview: http://www.broadinstitute.org/haploview/haploview). The plot includes
pairwise r
2 values from the HapMap release 24 for the JPT population. (B) Genes located at this locus. The asterisk indicates the SNP rs2268388 at
intron 18 of the ACACB. (C) Results of a case-control association study for diabetic nephropathy in 754 Japanese individuals with type 2 diabetes
having overt proteinuria and 558 control individuals with type 2 diabetes and normoalbuminuria. The log10-transformed p values for an additive
model are plotted on the Y-axis. The X-axis indicates chromosomal position at this locus.
doi:10.1371/journal.pgen.1000842.g001
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238.5681.9; relative luciferase activity, p=0.0005 for P vs. T,
p=0.016 for P vs. C). Fragments corresponding to the disease
susceptibility allele had stronger enhancer activity than those for
the major allele ([T] 10.563.4 vs. [C] 5.961.3, fold increase over
promoter alone, p=0.045, Figure 3B).
Discussion
In the present study, we showed ACACB located at chromosome
12q24.1 to be a strong susceptibility gene for diabetic nephropathy
in patients with type 2 diabetes. Our findings suggest that a SNP
within ACACB (rs2268388, intron 18 + 4139 C . T) contributes to
the development of proteinuria in patients with type 2 diabetes.
ACACB encodes acetyl-coenzyme A (CoA) carboxylase beta,
which catalyzes the carboxylation of acetyl-CoA to malonyl-CoA,
and controls fatty acid oxidation by means of the ability of
malonyl-CoA to inhibit carnitine palmitoyl transferase I (CPT1A;
MIM 600528), the rate-limiting step in fatty acid uptake and
oxidation by mitochondria in non-lipogenic tissues. Mice lacking
Acacb have a normal life span, a higher rate of fatty acid oxidation,
lower amounts of fat, and increased insulin sensitivity [19–21];
therefore, ACACB might affect insulin sensitivity via modulation of
fatty acid metabolism. However evidence suggesting a role for the
ACACB in the pathogenesis of diabetic nephropathy was previously
lacking. In this study, expression of ACACB was detected in heart,
skeletal muscle and adipose tissues by real-time quantitative
polymerase chain reaction (PCR) as previously reported [22]. We
also showed that ACACB was expressed in human kidney, and in
situ hybridization revealed that Acacb expression was localized to
glomerular epithelial cells and tubular epithelial cells in normal
mouse kidneys. Abnormalities in lipid metabolism [23,24],
including fatty acid metabolism have been shown to contribute
to the development and/or progression of chronic kidney diseases,
including diabetic nephropathy. Hence, genotype-based differenc-
es in expression and/or activity of this enzyme in the kidney might
contribute to conferring susceptibility to diabetic nephropathy.
Elucidating these functional differences will help us to
understand how variation in this gene contributes to susceptibility
to diabetic nephropathy. In this study, the 29-bp fragment that
included the landmark SNP (rs2268388) was shown to have
significant enhancer activity. We also demonstrated that the DNA
Table 2. Association of the SNP in the ACACB (rs2268388) with diabetic nephropathy in several independent cohorts.
Proteinuria
Populations
(a) Case
(b) Control
(b) p
(c) OR (95%CI)
Japanese 1 0.25 (413/276/48) 0.17 (379/155/18) 1.4610
26 1.61 (1.33–1.96)
Japanese 2 0.24 (18/11/2) 0.21 (106/47/10) 0.54 1.23 (0.65–2.34)
Japanese 3 0.29 (35/28/6) 0.22 (116/53/13) 0.09 1.49 (0.96–2.32)
Japanese meta-analysis
(d) 5.35610
28 1.61 (1.35–1.91)
Heterogeneity test 0.64
Singaporean Han Chinese 0.25 (108/83/8) 0.24 (119/86/7) 0.64 1.07 (0.78–1.48)
East Asian meta-analysis
(d) 5.54610
27 1.47 (1.26–1.71)
Heterogeneity test 0.12
European 1 (Steno 2 study) 0.23 (28/16/3) 0.17 (75/29/4) 0.2 1.48 (0.82–2.68)
Total meta-analysis
(d) 2.34610
27 1.47 (1.27–1.70)
Heterogeneity test 0.22
Total meta-analysis
(d) excluding Japanese 1 0.02 1.29 (1.03 – 1.62)
Heterogeneity test 0.30
ESRD
Populations Case Control p
b OR (95%CI)
Japanese 4 0.19 (196/90/12) 0.23 (136/67/18) 0.12 0.78 (0.58–1.05)
Korean 0.21 (110/58/9) 0.25 (110/75/11) 0.15 0.83 (0.59 – 1.17)
East Asian meta-analysis
(d) 0.05 0.80 (0.64–1.00)
Heterogeneity test 0.78
European 2 (Wake Forest) 0.17 (330/128/15) 0.11 (326/86/3) 0.0006 1.61 (1.22–2.13)
Total meta-analysis
(d) 0.47 1.07 (0.90–1.27)
Heterogeneity test 0.0006
Type 1 Diabetes
Populations Case Control p
b OR (95%CI)
Dane 0.17 (309/128/11) 0.15 (306/110/9) 0.33 1.13 (0.88–1.47)
(a)Japanese 1; case-control for a genome-wide association study.
(b)risk allele frequencies are shown, and genotype counts are in parenthesis.
(c)p values for additive model.
(d)combined results by using Mantel-Haenszel test.
doi:10.1371/journal.pgen.1000842.t002
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higher enhancer activity than that for the major allele in cultured
human RPTECs. Therefore, the intronic variation in the gene
seems to be causal. We hypothesize that higher expression of
ACACB in the kidneys of subjects having the disease susceptibility
allele (T) may increase the susceptibility to diabetic nephropathy in
type 2 diabetes.
Interestingly,the association of the T alleleof rs2268388 with type
2 diabetes-associated nephropathy was consistently observed in cases
with proteinuria, whereas there was less consistent association
between type 2 diabetic patients under chronic renal replacement
therapy (ESRD). Discrepancies in genomic loci underlying suscep-
tibility to proteinuria versus ESRD were previously noted in a
genome-wide linkage scan for diabetic nephropathy in type 2
diabetes [25]. Because most of the patients with ESRD were
considered to have had proteinuria, and there is significant
heterogeneity in the association with diabetic ESRD among the
East Asian and European American populations (heterogeneity
p=0.0006, Table 2), some selection bias, such as a survival effect, or
ethnicdifferencesmightexist whenpatientswith ESRDwere usedas
cases. Since the presence of proteinuria is also recognized as a
predictor of cardio-vascular diseases, the association of ACACB with
proteinuria might reflect an association between the gene and
cardio-vascular diseases or metabolic syndrome. However elucida-
tion of a precise mechanism will require further investigation.
Association of the ACACB with diabetic nephropathy could not
be replicated in patients with type 1 diabetes, although these
nephropathy cases had proteinuria. The clinical features or
histological characteristics of diabetic nephropathy are similar in
both type1 and type 2 diabetes mellitus; however, there are some
differences in the background circumstances between both types of
the disease. For example, patients with type 2 diabetes are
generally older, and more obese than those with type 1 diabetes.
Therefore, it is possible that genetic factors for nephropathy are
different for type 1 and type 2 diabetes, although some overlap
may exist. Because the statistical power of this study for patients
with type 1 diabetes was probably not sufficient, the association of
variations in ACACB with diabetic nephropathy in patients with
type 1 diabetes should be re-evaluated in future studies.
Recently, GWASs have been performed to identify susceptibil-
ity genes for common diseases. Convincing susceptibility genes for
many diseases including type 2 diabetes have been successfully
Figure 2. Expression profiles of ACACB. (A) Expression profiles of ACACB in various human tissues evaluated by real-time PCR. (B) Results of in situ
hybridization for 20-week-old normal mouse kidneys using mouse Acacb anti-sense (left) and sense (right) probes.
doi:10.1371/journal.pgen.1000842.g002
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conducted in the Genetics of Kidneys in Diabetes (GoKinD)
collection, and several novel loci were identified for diabetic
nephropathy in type 1 diabetes [11]. Compared to our study,
recent GWASs conducted in European and American groups had
greater power to detect true associations. The power of the first
and second test in the present study is estimated .40% and .90%
respectively, for SNPs with minor allele frequency of 0.2 as in our
sample, if we set a cut-off value at the p=0.05 level, a genotypic
relative risk (c) of 1.5, and the prevalence of diabetic nephropathy
is assumed to be 10% (CaTS power calculator, CaTS: http://
www.sph.umich.edu/csg/abecasis/CaTS/). Therefore, other im-
portant loci contributing to diabetic nephropathy in Japanese
populations may not have been detected and should be searched
for using a larger scale of GWAS. Limitations exist in increasing
the numbers of subjects with diabetic nephropathy and diabetes
lacking nephropathy in single center studies. Therefore, we
examined several independently collected study populations,
allowing for the presence of different selection criteria and the
small sample size in some replication cohorts. Future analyses
should attempt to avoid these limitations so as not to produce
spurious results.
In summary, based upon extensive genome-wide gene-centric
SNP analyses, we identified ACACB as a candidate gene for
conferring susceptibility to diabetic nephropathy. Subsequent
replication studies in several different ethnic groups and a functional
study suggest that the T-allele of a common intronic SNP
(rs2268338) within ACACB is a risk factor for the development
and progression of proteinuria in patients with type 2 diabetes.
Materials and Methods
Subjects, DNA preparation, and genotyping
Japanese 1 (genome-wide screening); DNA samples were
obtained from the peripheral blood of patients with type 2 diabetes
who regularly attended outpatient clinics at Shiga University of
Medical Science, Tokyo Women’s Medical University, Juntendo
University, Kawasaki Medical School, Iwate Medical University,
Toride Kyodo Hospital, Kawai Clinic, Osaka City General
Hospital, Chiba Tokusyukai Hospital or Osaka Rosai Hospital.
All subjects provided informed consent before enrolling in this
study. DNA extraction was performed by a standard phenol-
chloroform method. Diabetic patients were divided into 2 groups
according to the following diagnostic criteria: 1) nephropathy cases,
i.e., patients with diabetic retinopathy and overt nephropathy,
indicated by a urinary albumin excretion rate (AER) $200 mg/min
ora urinaryalbumin/creatinineratio(ACR)$300 mg/gcreatinine
(Cr), and 2) control patients who have diabetic retinopathy but no
evidence of renal dysfunction (i.e. AER less than 20 mg/min or
ACR less than 30 mg/g Cr). Measurements of AER or ACR were
performed at least twice for each patient. The SNPs for genotyping
were randomly selected from our gene-based Japanese SNP (JSNP)
database. The genotype of each SNP locus was analyzed with
multiplex PCR-invader assays, as described previously [14–16].
Our first screening involved genotyping 94 nephropathy cases
and 94 control patients for more than 100,000 SNP loci. In total,
76,767 SNP loci, which distributed to 13,707 gene-centric regions
and covered approximately 35% of common SNPs (MAF .0.15)
in these regions, were successfully genotyped by the invader assay
(success rates .0.95). We estimated identity by descent (IBD)
sharing to assess relatedness among our initial GWAS populations.
As shown in Figure S2, the result indicates that there were no close
relative pairs in this population. We also performed principal
component analysis (PCA) using our initial GWAS populations to
evaluate population structures. Since all subjects were in a single
cluster in the PCA analysis (Figure S3), no evidence for population
stratification between case and control groups appeared to exist in
the present GWAS.
After the first round of analysis that evaluated SNPs with p
values less than 0.01 in the first screening (previously published
[14–16]), we extended our analysis to include SNPs with p values
between 0.01 and 0.05 and examined them in a larger number of
patients (754 nephropathy cases vs. 558 control patients). The
study protocol was approved by the ethics committees of RIKEN
Yokohama Institute and each participating institution.
Subjects in replication studies
Japanese replication studies. We obtained DNA samples
from 2 longitudinal studies (Japanese 2, Japanese 3) and one case-
control study (Japanese 4).
Figure 3. Effect of a 29-bp DNA fragment containing the associated SNP (rs2268388) on transcriptional activity in cultured
hRPTECs. (A) A 29-bp sequence including SNP rs2268338. Overhung sequences are compatible ends for concatenation. (B) Enhancer activities of the
DNA fragments corresponding to each allele in human RPTECs. Results are shown as mean 6 SD of the ratio of activity to that of the promoter alone
obtained from 4 independent experiments. * p=0.045 vs. major allele.
doi:10.1371/journal.pgen.1000842.g003
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among the participants in the Shiga Prospective Observational
Follow-Up Study for Diabetic Complications [26]. On the basis of
at least 2 measurements of AER in 24-h urine collections, those
classified as having microalbuminuria (200 mg/min . AER
$20 mg/min) were followed for up to 6 years. The progressors
(cases) were defined as those had progressed to overt proteinuria
(AER $200 mg/min, n=32), and the remaining patients were
defined as non-progressors (controls, n=168). The ACACB
genotype was analyzed with multiplex PCR-invader assays. The
study protocol and informed consent procedure were approved by
the ethics committee of Shiga University of Medical Science.
Japanese 3; Patients with type 2 diabetes and normoalbuminuria
or microalbuminuria, as determined by at least two measurements
of ACR or AER (normoalbuminuria; ACR ,30 mg/g Cr or AER
,20 mg/min, microalbuminuria; 30# ACR ,300 mg/g Cr or
20# AER ,200 mg/min) who could be followed for 10 years were
recruited from among diabetic outpatients at Juntendo University
Hospital or Saiseikai Central Hospital [27]. Progressors (cases,
n=71) were defined as patients who progressed from a given stage
to a more advanced stage of diabetic nephropathy; the remaining
patients were defined as non-progressors (controls, n=193). The
ACACB genotype was analyzed with multiplex PCR-invader assays.
All patients gave informed consent and the protocol was approved
by the ethics committee of Juntendo University or that of Saiseikai
Central Hospital.
Japanese 4; Patients with type 2 diabetes regularly visiting Tokai
University Hospital or its affiliated hospitals were enrolled. All
nephropathy cases were receiving chronic hemodialysis therapy
(n=300), and control patients were those with normoalbuminuria
determined by at least 2 measurements of the urinary ACR, and
diabetes for more than 10 years (n=218). The ACACB genotype
was analyzed with multiplex PCR-invader assays. Patients gave
informed consent and the protocol was approved by the ethics
committee of Tokai University School of Medicine.
Korean replication study. Korean patients with type 2
diabetes comprising two groups according to the following criteria
were examined [28]: 1) the control group (n=196): patients with
diabetic retinopathy and who had diabetes for more than 15 years
but no renal involvement (i.e., ACR,30 mg/g Cr and creatinine
clearance [using the Cockroft equation] of .60 ml/min per
1.73 m
2); 2) the ESRD group (n=177): patients with diabetic
retinopathy and ESRD due to type 2 diabetes, as indicated by a
creatinine clearance rate of ,15 ml/min per 1.73 m
2 or receiving
renal replacement therapy. The TaqMan method for genotyping
was applied in the Korean replication study. The institutional
review board of the Clinical Research Institute at Seoul National
University Hospital approved the study protocol, and informed
consent for genetic analysis was obtained from each patient.
Singaporean replication study. Cases and controls were
selected from Chinese patients with type 2 diabetes who had been
enrolled into the Singapore Diabetes Cohort Study (SDCS) as
previously reported [29]. Patients with ACR .300 mg/g Cr or
dipstick positive were considered nephropathy cases (n=199).
Controls were patients who were normalbuminuric with ACR
,30 mg/g Cr and had diabetes for more than 7 years (n=212).
The ACACB genotype was analyzed using a Taqman genotyping
assay available from Applied Biosystems (Foster city, CA, U.S.A.).
The research protocol for SDCS was approved by both the
National University of Singapore Institutional Review Board
(NUS-012) and the National Healthcare Group Domain-Specific
Review Board (C/05/118).
European replication studies. European 1 (Steno 2):
Patients were recruited from the Steno Diabetes Center between
1992 and 1993. Microalbuminuria was defined as an AER of
30–300 mg per 24 h in 4 of 6 samples of sterile urine. These
patients were enrolled and followed up for an average of 7.8 years
[30]. Patients who progressed to nephropathy (AER .300 mg per
24 h, n=47) were used as cases, and the remaining patients were
defined as controls (n=110). The ACACB genotype was analyzed
with multiplex PCR-invader assays. Informed consent was
obtained from all participants. The protocol was in accordance
with the Declaration of Helsinki and was approved by the ethics
committee of Copenhagen County.
European 2 (Wake Forest): Patients with European ancestry
who were born in North Carolina, South Carolina, Georgia,
Tennessee, or Virginia were enrolled. Cases all had type 2 diabetes
mellitus for 5 or more years before the development of ESRD with
overt proteinuria and/or diabetic retinopathy (n=481). Control
patients had type 2 diabetes for more than 5 years with ACR
,30 mg/g Cr and serum creatinine ,1.5 mg/dl (n=427). The
ACACB SNP was genotyped using the MassARRAY genotyping
system (Sequenom, San Diego, CA, U.S.A.). PCR primers were
designed using the MassARRAY Design 3.4 Software (Sequenom).
This study was conducted under Institutional Review Board
approval from Wake Forest University School of Medicine, and
adhered to the tenets of the Declaration of Helsinki.
Type 1 diabetes: Adults with type 1 diabetes attending the
outpatient clinic at the Steno Diabetes Center were invited to
participate in a study of genetic risk factors for the development of
diabetic micro- and macrovascular complications [31]. Patients
were considered to have type 1 diabetes if the age at onset of
diabetes was #35 years and if the time to definitive insulin therapy
was #1 year. Established diabetic nephropathy (cases, n=458)
was defined as persistent albuminuria ($300 mg/24 h) in 2 out of
3 consecutive measurements on sterile urine in the presence of
retinopathy. The absence of diabetic nephropathy (controls,
n=442) was defined as persistent normoalbuminuria (urinary
albumin excretion rate: ,30 mg/24 h) after at least 15 years of
diabetes duration in patients not treated with angiotensin
converting enzyme inhibitors or angiotensin II receptor blockers.
The ACACB genotype was analyzed with multiplex PCR-invader
assays. The study was performed in accordance with the
Declaration of Helsinki. The local ethics committee approved
the study and all patients gave their informed consent.
The clinical characteristics of patients in all studies are shown in
Table S2.
Real-time quantitative RT–PCR
We obtained human cDNAs from multiple tissues from
CLONTECH Inc. (Palo Alto, CA, U.S.A.). The cDNAs were
amplified by PCR with the following primers: human ACACB, sense
59-CGG ATG CGT AAC TTC GAT CTG-39, antisense 59-CTA
TGG TCC GTC ACT TCC ACA C-39; BACT, sense 59- TCA
CCC ACA CTG TGC CCA TCT ACG A -39, antisense 59- CAG
CGG AAC CGC TCA TTG CCA ATG G -39. Amplification was
performed in a 22 ml reaction volume that contained 16EX Taq
Buffer, 200 nM dNTP, 1/20,000 SYBR Green, 0.2 mM Rox,
800 nMgene-specificprimer,0.05 U/mlEXTaqHotStartVersion
(Takara, Otsu, Japan), and 5 ng of template DNA. The thermal
profile was 50uC for 2 min, at 95uC for 10 min, followed by 40
cycles at 95uC for 30 s and at 60uC for 60 s in thermal cycler
(Mx3000P Multiplex Quantitative PCR system; Stratagene, La
Jolla, CA, U.S.A.). The results were normalized with human BACT.
In situ hybridization
Under pentobarbital anesthesia, 20-week-old mice were flushed
with PBS through the abdominal aorta followed by perfusion with
ACACB and Diabetic Nephropathy
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were quickly removed and cut into small pieces. The renal cortex
tissue was immediately dissected and immersed into a fresh portion
of the same fixative at 4uC overnight. All steps were carefully carried
out to avoid contamination with RNase. Diethylpyrocarbonate-
treated water was used at 0.1% to prepare each buffer. The fixed
samples were thoroughly rinsed with PBS (pH 7.4) and subsequently
dehydrated by passage through an alcohol series and cleared in
xylene. In situ hybridization was performed on paraffin-embedded
sections using a previously described method [15]. Antisense and
sense single-strand cRNAs were synthesized from cDNA fragments
encoding Acacb using reverse-transcription PCR. The Acacb cDNA
fragment was consisted of a 500 bp mouse sequence (nucleotides
181–680, GenBank accession number NM_133904, GenBank:
http://www.ncbi.nlm.nih.gov/Genbank/).
Plasmid construction and transfection experiments
Three copies of the 29-bp DNA fragments including rs2268388
in ACACB were subcloned into a pGL3-promoter vector (Promega,
Madison, WI, U.S.A.) at its multi-cloning site upstream of the SV-
40 promoter. We introduced constructs corresponding to each
allele into the human renal proximal tubular epithelial cells
(hRPTEC, Lonza, Basel, Switzerland) along with a sea-pansy
luciferase control vector, pRL-TK (Promega), using the liposome
transfection procedure (Lipofectoamine 2000, Life Technology
Inc, Carlsbad, CA, U.S.A.). Twenty-four hours after transfection,
luciferase activitiy was determined by means of the Dual
Luciferase Reporter Assay System (Promega). The luminescence
of firefly luciferase was corrected by use of the sea-pansy luciferase,
which reflected transfection efficiency.
Statistical analyses
We tested the genotype and allele frequencies for Hardy-
Weinberg equilibrium (HWE) proportions by use of the x
2 test
[32]. We calculated the LD index, D’ and r
2, as described
elsewhere [33]. We analyzed the differences between the case and
control groups with regard to the genotype distribution and allele
frequency in the genome-wide screen by Fisher’s exact test with
dominant, recessive and allelic models with autosomal SNPs. The
association of the ACACB locus with diabetic nephropathy in the
replication study was evaluated with the Armitage test for trends
using an additive model, as described previously [34]. Combined
meta-analysis was performed by using the Mantel-Haenszel
procedure with a fixed effect model after testing for heterogeneity.
The data from the transfection experiments were analyzed by one-
way analysis of variance, followed by Scheffe’s test to evaluate
statistical differences among 3 groups or by an un-paired t test to
evaluate differences between 2 groups.
Supporting Information
Figure S1 Haplotype frequencies and the association of
haplotypes in the ACACB with diabetic nephropathy. Fifty-one
SNPs within the ACACB were genotyped in 754 nephropathy
cases and 558 controls. Nine haplotype blocks are identified using
Gabriel’s Method by Haploview.
Found at: doi:10.1371/journal.pgen.1000842.s001 (0.58 MB EPS)
Figure S2 Estimation of IBD sharing among subjects in the
genome-wide screening.
Found at: doi:10.1371/journal.pgen.1000842.s002 (0.24 MB EPS)
Figure S3 Quality control for the genome-wide screening. (A)
Principal Compornent Analysis (PCA) (B) quantile-quantile plot.
Found at: doi:10.1371/journal.pgen.1000842.s003 (0.42 MB EPS)
Table S1 Association of SNPs in the ACACB gene with diabetic
nephropathy in Japanese subjects with type 2 diabetes. (A) tagging
SNPs to cover this locus are shown in bold. (B) Minor allele
frequencies are presented. Genotype counts are in parenthesis. 11;
homozygous for major allele, 12; heterozygous, 22; homozygous
for minor allele. (C) p values for the additive model.
Found at: doi:10.1371/journal.pgen.1000842.s004 (0.14 MB
DOC)
Table S2 Clinical characteristics of the subjects. Values are
mean 6 SE, NA: not available. (A) Data at baseline are presented.
(B) 5 unknown. (C) 6 unknown. (D) p,0.05 versus control.
Found at: doi:10.1371/journal.pgen.1000842.s005 (0.09 MB
DOC)
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